

TKL Research Expands Capability in Europe

ROCHELLE PARK, NJ (June 8, 2010)—TKL Research, (www.tklresearch.com) a full-service US-based clinical research organization (CRO) that focuses on enrollment-driven Phase I-IV clinical trials announced an expansion of its presence and capabilities in Europe by taking an equity position in *proinnovera* GmbH, a full-service CRO based in Münster, Germany.

Jon C. Anderson, PhD, TKL President and CEO, said, “This significantly expands our capabilities throughout Europe and enables TKL to meet the increasing demand for international trials by our current and future clients. Our past success in conducting quality clinical trials in Europe will be further enhanced by having a European office in Germany. This partnership will significantly increase TKL’s capacity to provide services to more US-based sponsors looking for clinical trial services in Europe. We will be better established in Europe, have a solid understanding of European sites, offer a dynamic network of medical specialists and hospitals, and, as with our US operations, apply this expertise to accelerate patient enrollment.”

Robert C. Reardon, PhD, Executive Vice President and COO of TKL, added, “Having a base in the US and in Europe will facilitate providing services to our clients for Phase I-IV studies. Our reputation for reducing clinical trial timelines by taking responsibility for enrollment and site selection was an important element in our decision to move forward with *proinnovera*. Both of our organizations excel at enrollment-driven trials. Both are committed to quality Phase I-IV clinical research, work closely with sponsors to help evaluate sites’ capabilities, and deliver subjects ahead of schedule. This similar approach to clinical trials will provide our clients with seamless study management and expanded capabilities.”

About TKL Research

TKL Research is a US-based clinical research services company offering complete Phase I-IV clinical trial services in several enrollment-driven therapeutic areas. These include dermatology, allergy/respiratory, diabetes, gastroenterology, and women’s health. TKL also has 5 research clinics in the NY metropolitan area for single-center Phase I-IV clinical trials for pharmaceutical, biologic, medical device, and consumer pharmaceutical products.

About *proinnovera* GmbH

proinnovera is a Germany-based CRO offering a full range of clinical research services for Phase I-IV clinical trials throughout Europe. The company offers expertise in several therapeutic areas including dermatology, pain management, allergy/respiratory, oncology, and vaccines. *proinnovera* provides a comprehensive range of clinical trial services including monitoring, medical affairs, project management, regulatory and consulting services for pharmaceutical, biotech, and medical device development programs.